Welcome to our dedicated page for Cytokinetics SEC filings (Ticker: CYTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cytokinetics, Incorporated filings document a specialty cardiovascular biopharmaceutical company with common stock listed on the Nasdaq Global Select Market. Its 8-K reports cover financial results, corporate presentations, MYQORZO® regulatory approvals, clinical and regulatory disclosures, and material capital-structure events such as underwriting agreements for common stock offerings.
Proxy materials describe board elections, executive compensation, auditor ratification and equity plan amendments, including matters tied to the company’s employee stock purchase plan. Other filings address governance changes, risk disclosures, registered securities, exhibits and Inline XBRL cover-page data associated with Cytokinetics’ public-company reporting obligations.
Cytokinetics Inc President & CEO Robert I. Blum reported an open-market sale of 7,500 shares of common stock at $70.46 per share. After this transaction, he directly holds 385,330 shares. In addition, 2,083 shares are held indirectly by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares are held indirectly by The Brittany Blum 2003 Irrevocable Trust.
CYTOKINETICS INC EVP Research & Development Fady Ibraham Malik reported an option exercise paired with a share sale. On June 9, 2026, he exercised options to acquire 3,500 shares of common stock at $7.80 per share and sold 3,500 shares in an open-market transaction at $67.98 per share.
Following these transactions, he directly owned 153,902 shares of common stock and held 44,386 non-qualified stock options. The activity reflects converting a portion of stock options into shares and immediately selling an equivalent number of shares for cash while retaining a substantial remaining equity position.
CYTOKINETICS INC director Edward M. Kaye, MD sold shares in the company. He completed an open-market sale of 2,933 shares of Common Stock at a price of $76.09 per share. After this transaction, he directly holds 10,283 shares of Cytokinetics common stock.
CYTOKINETICS INC executive Andrew Callos reported an option exercise and share sale. On 2026-06-01, he exercised non-qualified stock options to acquire 15,000 shares of Common Stock at $23.26 per share, then sold 15,000 shares in an open-market sale at $74.08 per share.
Following these transactions, Callos directly held 58,555 shares of Common Stock. The exercised stock options were part of an award that vests over four years from grant, with 25% vesting after one year and the remainder vesting monthly over the next 36 months, subject to continued employment.
CYTOKINETICS INC director Lynne Parshall sold shares in the company. On June 1, 2026, she executed an open-market sale of 5,000 shares of Common Stock at $74.08 per share. After this transaction, she directly holds 15,784 shares of Cytokinetics common stock.
Cytokinetics Inc. President and CEO Robert I. Blum reported an open-market sale of 7,500 shares of common stock at $77.21 per share. Following this sale, he holds 392,830 shares directly. Separate trust holdings reported as of the same date each hold 2,083 shares indirectly.
CYTOKINETICS INC director Muna Bhanji received new equity compensation. On 2026-05-27, Bhanji was granted 2,851 shares of common stock at no cost, increasing direct holdings to 26,361 shares.
Bhanji was also awarded a non-qualified stock option for 4,301 shares of common stock at an exercise price of $77.15 per share. The option becomes exercisable on 2026-06-28 and expires on 2036-05-26.
CYTOKINETICS INC director James M. Daly received new equity awards in the form of shares and stock options. He was granted 2,851 shares of Common Stock at no cost, increasing his direct holdings to 3,239 shares. He also received a non-qualified stock option covering 4,301 shares of Common Stock at an exercise price of $77.15 per share. This option becomes exercisable starting on June 27, 2026 and expires on May 26, 2036, reflecting routine equity-based director compensation rather than an open-market purchase.
Harrington Robert Arthur reported acquisition or exercise transactions in this Form 4 filing.
Cytokinetics director Robert Arthur Harrington received equity compensation in the form of common stock and stock options. He was granted 2,851 shares of common stock and now holds 21,781 shares directly.
He was also granted 4,301 non-qualified stock options exercisable at $77.15 per share, expiring on May 26, 2036, linked to 4,301 shares of common stock.